Committee seeks stronger trial design, urging SII to sharpen objectives and raise scientific standards for proving CERVAVAC’s ...

Thierry André and colleagues recently reported that nivolumab–ipilimumab provided an impressive absolute progression-free survival benefit at 36 months, which was 17% compared with nivolumab ...

Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED technology and materials, today announced that it has entered into a defini ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to ...

Merck's power purchase agreement (PPA) with SK Innovation E&S will supply 16 megawatts of renewable electricity to life ...

German diversified group Merck KGaA is preparing to put its pigments business up for sale to fund investments at its drugs ...

Although Merck (currently trading at $84.57 per share) has gained 7% over the last six months, it has trailed the S&P 500’s ...

Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...

Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 ...

Donald Trump’s man in London reiterated the US president’s demands for the UK to pay pharmaceutical companies more money.